RecruitingPhase 1NCT06153251

A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma

Sponsor

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Enrollment

187 participants

Start Date

Jan 23, 2024

Study Type

INTERVENTIONAL

Conditions

Relapsed and/or Refractory Multiple Myeloma

Summary

The purpose of this study is to assess BMS-986453 in participants with relapsed and/or refractory multiple myeloma (RRMM).

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This trial is testing a new investigational drug called BMS-986453 in people with multiple myeloma that has returned or stopped responding to treatment. BMS-986453 is an experimental therapy aimed at targeting myeloma cells in patients whose cancer has progressed despite prior treatment with a proteasome inhibitor (like bortezomib) and an immunomodulatory drug (like lenalidomide). **You may be eligible if...** - You have been diagnosed with multiple myeloma that has relapsed or is no longer responding - Your myeloma progressed within 12 months of your last treatment - You have previously received both a proteasome inhibitor and an immunomodulatory agent - You are in reasonably good health (ECOG 0 or 1) with adequate organ function **You may NOT be eligible if...** - Your multiple myeloma has spread to the brain or spinal fluid - You have plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome, or significant amyloidosis - You have a significant neurological condition such as stroke, severe brain injury, dementia, Parkinson's disease, or active psychosis Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBMS-986453

Specified dose on specified days

DRUGFludarabine

Specified dose on specified days

DRUGCyclophosphamide

Specified dose on specified days

Locations(19)

University of Alabama at Birmingham

Birmingham, Alabama, United States

City of Hope Comprehensive Cancer Center

Duarte, California, United States

UCSF Helen Diller Medical Center at Parnassus Heights

San Francisco, California, United States

Stanford University Medical Center

Stanford, California, United States

Colorado Blood Cancer Institute

Denver, Colorado, United States

Yale Cancer Center

New Haven, Connecticut, United States

Moffitt Cancer Center

Tampa, Florida, United States

Dana-Farber Cancer Institute

Boston, Massachusetts, United States

Icahn School of Medicine at Mount Sinai

New York, New York, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Local Institution - 0008

Nashville, Tennessee, United States

Tennessee Oncology

Nashville, Tennessee, United States

Swedish Medical Center

Seattle, Washington, United States

Hôpital Saint-Louis

Paris, France

Universitaetsklinikum Koeln

Cologne, Germany

Universitaetsklinikum Heidelberg

Heidelberg, Germany

Universitaetsklinikum Wuerzburg

Würzburg, Germany

Clinica Universidad de Navarra

Pamplona, Navarre, Spain

Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca

Salamanca, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06153251

Related Trials

OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM

NCT061826965 locations

Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma

NCT057197016 locations